8th RAS-Targeted Drug Development Summit
September 8 - 10, 2026 - MA USHanson Wade
info@hansonwade.com
Phone:+1 415 735 3289
RAS-targeted drug development has entered a pivotal new phase. Once considered "undruggable," RAS is now one of oncology's most competitive and fast-moving therapeutic frontiers, with next-generation inhibitors, pan-RAS strategies, novel modalities, and complex combination approaches advancing in parallel. As programmes expand beyond G12C into G12D, G12V, G13D, and multi-variant targeting, the challenge has shifted from discovery to delivering durable clinical impact. The 8th RAS-Targeted Drug Development Summit is the industry's only forum dedicated exclusively to translating RAS therapies from early discovery through clinical development. Bringing together leaders across biopharma, including Bristol Myers Squibb, Amgen, Revolution Medicines, Verastem, Incyte, Jacobio Pharmaceuticals and NCI the meeting focuses on overcoming resistance, improving therapeutic durability, and accelerating development timelines. Join senior RAS-focused experts to gain actionable insights on next-generation targeting strategies, innovative modalities, smarter combination design, and precision patient stratification, equipping you to advance more effective RAS therapies for broader patient populations. Time: 8:00 AM - 4:15 PM